

AACR Special Conference in Cancer Research

Bladder Cancer: Transforming the Field


May 17–20, 2024 | Charlotte, NC

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Abbosh	Philip	Janssen Pharmaceuticals, abyost, Natera, Janssen Pharmaceuticals	IC, OBO, GC, GC	Speaker
Abrahimi	Parwiz	Patent	P	Speaker
Alam	Syed	No Relationships		Speaker
Allenspach	Karin	Royal Canin, 3D Health Solutions, Inc., CEVA Sante Animale	IC, OBO, IC	Speaker
Arthur	Ronald	No Relationships		Staff
Athans	Sarah	No Relationships		Speaker
Banday	Rouf	No Relationships		Speaker
Barragan-Carrillo	Regina	No Relationships		Speaker
Beachy	Philip	No Relationships		Speaker
Bhardwaj	Nina	BreakBio, Rome Therapeutics, cell bioengines	IC, IC, S	Speaker
Chou	Jonathan	Exai Bio	IC	Speaker
Dyrskjøt	Lars	UROGEN PHARMA, INC., Natera, Photocure Inc, AstraZeneca, Ferring Pharmaceuticals AS, Ferring Pharmaceuticals AS, Pfizer, C2i Genomics	IC, GC, GC, GC, GC, IC, IC, GC	Program Committee, Speaker
Eckstein	Markus	Janssen Research and Development, Gilead Sciences Inc, Merck Sharp and Dohme, Gilead Sciences Inc, Owkin, Owkin, AstraZeneca, Janssen Research and Development, Stratifyer	IC, GC, IC, IC, IC, GC, GC, GC, GC	Speaker



AACR Special Conference in Cancer Research

Bladder Cancer: Transforming the Field

May 17–20, 2024 | Charlotte, NC

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Kristjánsdóttir	Nanna	No Relationships		Speaker
Kuhn	Peter	Epic Sciences, Epic Sciences, Earli, Cansera	S, IC, SO, IC	Speaker
Lee	Cheryl	UROGEN PHARMA, INC.	IC	Speaker
Levy	Joshua	No Relationships		Speakercheck
Li	Zihai	No Relationships		Speaker
Lindskrog	Sia	No Relationships		Speaker
Mahmood	Faisal	No Relationships		Speaker
McConkey	David	No Relationships		Speaker
Merrill	Nathan	No Relationships		Speaker
Milowsky	Matthew	Merck, Bristol-Myers Squibb, Mirati Therapeutics, Seagen Inc., Alliance Foundation Trails, Arvinas, ALX Oncology, Novartis, Acrivon Therapeutics, Astellas Pharma, Genentech, Accuray, PCCTC, G1 Therapeutics, OncoC4, Falre Therapeutics, Loxo/Lilly, Roche, Pfuzer, Merck, Gilead Sciences, Elsevier, Medscape, Research to Practice, G1 Therapeutics, Loxo/Lilly	GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, S, S, S	Speaker
Parada	Luis	No Relationships		Speaker
Simon	Nicholas	No Relationships		Speaker
Solit	David	Vividion Therapeutics, Function Oncology, FORE Therapeutics, Pfizer, BridgeBio, Elsie Biotechnology, Rain Therapeutics, Scorpion Therapeutics	IC, SO, IC, O, IC, SO, IC, IC	Speaker
Strandgaard	Trine	No Relationships		Speaker
Sullivan	James	enGene	E	Speaker
Teoh	Jeremy	No Relationships		Speaker
Theodorescu	Dan	No Relationships		Program Committee, Speaker
Thoppil	Roslin	No Relationships		Staff
Wobker	Sara	No Relationships		Speaker
Zuiverloon	Tahlita	Merck, InnoSign	IC, O	Program Committee, Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.